# Determination of the Optimal Volume of Liposomal Bupivacaine in Adductor Canal Block for Knee Joint Surgery

> **NCT06942689** · PHASE4 · RECRUITING · sponsor: **Nanjing First Hospital, Nanjing Medical University** · enrollment: 63 (estimated)

## Conditions studied

- Optimal Volume of Liposomal Bupivacaine

## Interventions

- **DRUG:** Perform adductor canal block with liposomal bupivacaine.

## Key facts

- **NCT ID:** NCT06942689
- **Lead sponsor:** Nanjing First Hospital, Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06942689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06942689, "Determination of the Optimal Volume of Liposomal Bupivacaine in Adductor Canal Block for Knee Joint Surgery". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06942689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*